Company Overview of Actavis Pharma Inc.
Actavis Pharma Inc. develops, manufactures, and markets generic pharmaceutical products. It offers solid dosage and sterile dosage generic products. It was formerly known as Watson Pharma, Inc. The company was founded in 1931 and is based in Florham Park, New Jersey. As of August 28, 2000, Actavis Pharma Inc. operates as a subsidiary of Actavis plc.
100 Campus Drive
Florham Park, NJ 07932
Founded in 1931
Key Executives for Actavis Pharma Inc.
Senior Vice President of Strategic Development
Senior Vice President of Technical Operations
Compensation as of Fiscal Year 2014.
Actavis Pharma Inc. Key Developments
Actavis Pharma Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2014
Apr 30 14
Actavis Pharma reported unaudited earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported net revenues of $2,264.9 million compared to $1,664.5 million a year ago. Adjusted gross profit was $1,406.2 million compared to $883 million a year ago. Net revenue increased 36% due to the acquisition of Warner Chilcott, new product launches, and higher international net revenue. Adjusted gross margin as a percentage of adjusted net revenues within Actavis Pharma increased to 65.3% in the first quarter of 2014 from 52.7% in the first quarter of 2013, as a result of the acquisition of Warner Chilcott in the fourth quarter of 2013. Adjusted net revenues were $2,152.82 million compared to $1,674.3 million a year ago.
Fish & Richardson Wins Patent Infringement Suit for Allergan over Generic LUMIGAN(R) 0.01%
Jan 15 14
Fish & Richardson announced that it won an important Hatch-Waxman litigation for client Allergan, Inc. in a patent infringement suit against Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co., Inc., Watson Laboratories, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. On January 14, 2014, the U.S. District Court for the Eastern District of Texas ruled that the defendants could not sell their generic versions of Allergan's popular LUMIGAN(R) (bimatoprost ophthalmic solution) 0.01% until Allergan's last patent expires in 2027. LUMIGAN(R) 0.01 is a leading treatment for elevated eye pressure in people with glaucoma or ocular hypertension. LUMIGAN(R) 0.01% was first approved by the FDA in 2010. Under Hatch-Waxman, drug companies may file a so-called abbreviated new drug application (ANDA) with the FDA to seek approval for generic versions of already-approved drugs by submitting bioequivalence studies instead of clinical studies, which is a much cheaper method than the normal FDA process. Branded companies that own the patents and believe the generic will infringe must then sue to enforce their patent rights to attempt to prevent the approval of the infringing generic. As part of the ruling, the court permanently enjoined the defendants from the commercial manufacture, use, offer to sell and/or sale of their proposed generic products in, as well as the import of those products into, the U.S. or its territories.
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
May 9 13
Shire plc announced that its subsidiary, Shire Development LLC, has prevailed in its litigation against Watson Pharmaceuticals Inc., Watson Laboratories, Inc.-Florida, Watson Pharma, Inc. and Watson Laboratories, Inc. in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA(R) (mesalamine) delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. Shire's LIALDA remains the only once-daily mesalamine product indicated for both the induction of remission of mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. No ANDA's have been approved for generic versions of LIALDA.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|